Drugs / STEM-PD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05635409 | Nov 2022 → Jan 2027 expected | Parkinson disease | Region Skane | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STEM-PD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05635409 ↗ |
| Action | Restore | “Intracerebral transplantation of stem cell-derived dopaminergic progenitors to replace lost endogenous dopaminergic neurons offers a new potentially restorative therapeutic...” PMID 42426223 ↗ Jul 2026 |
| Modality | Cell therapy | “new stem cell therapy, called the STEM-PD product” NCT05635409 ↗ |
| Route | Other | “STEM-PD will be administered using a non-CE marked class III neurosurgical medical device, the Rehncrona-Legradi device, bilaterally in one surgical session to the putamen.” NCT05635409 ↗ |